Cancer Drug Resistance is a peer-reviewed journal led by Editor-in-Chief Godefridus J. (Frits) Peters, covering drug resistance research on breast cancer, lymphatic cancer, hematological malignancies, thyroid cancer, lung cancer, stomach cancer, esophage
Cancer Drug Resist 2020;3:832-53 I http://dx. malignant cells along the epithelial to mesenchymal axis. High-dimensional single cell analyses of specimens collected in ongoing clinical studies is becoming a key contributor to our understanding of these interactions. This review will explore to ...
第一篇Review article类型的文章“Protein degradation: expanding the toolbox to restrain cancer drug resistance”于2022年09月24号投稿,2023年01月01号接收,从投稿到接收用时3个多月,接收后01月24日Online,用时23天在线。 第二篇Research article类型的文章“Plasma extracellular vesicle messenger RNA profiling...
cancer drug resistance(癌症药物抗性) therapeutic strategies(治疗策略) targeted therapy(靶向疗法) 研究背景 APOBEC3胞苷脱氨酶已被确认为多种肿瘤类型的突变发生关键驱动因素,参与促进肿瘤演化和耐药性。 近年来的大规模测序研究揭示了人类癌症的基因组景观,发现APOBEC3介导的C>T/G>A突变在许多癌症类型中占主导地位...
Review Open Access Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer Yunchang Li, ... Chuan Xu How to Cite Li Y, Hu L, Peng X, Xu H, Tang B, Xu C. Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer. Cancer Drug Re...
decoys for antibody-based therapies.In this review,we discuss the various mechanisms of therapy resistance in GBM,highlighting the emerging role of EV-orchestrated drug resistance.Understanding the landscape of GBM resistance is critical in devising novel therapeutic approaches to fight this deadly ...
The research on drug resistance-related microRNAs (miRNAs) may eventually lead to improved clinical strategies and outcomes for patients with esophageal cancer (EC).This review summarizes the recent advances in drug resistance-related miRNAs in EC, and also analyzes the clinical and therapeutic ...
show activation of CYP1B1 expression. McFadyen described briefly the main strategies that are being used to tackle P450-associated drug resistance: (a) the use of prodrugs, (b) clinical inhibitors, and (c) immunotherapy; for a detailed review seeMcFadyen et al (2004). Since CYP1B1 is exc...
USPs have been recognized as key regulators of drug resistance across a spectrum of treatment modalities, including chemotherapy, targeted therapy, immunotherapy, and radiotherapy. This comprehensive review examines the complex relationship between USPs and drug resistance mechanisms, focusing on specific trea...
Cancer Drug Resistance Editor-in-Chief: Godefridus J. Peters Hepatoma Research Editor-in-Chief: Guang-Wen Cao News 2024 Annual Report ofJournal of Cancer Metastasis and Treatment Celebrating the 10th Anniversary ofJournal of Cancer Metastasis and Treatment...